Weekly Investment Analysts’ Ratings Changes for Oculis (OCS)

Several analysts have recently updated their ratings and price targets for Oculis (NASDAQ: OCS):

• 6/11/2026 – Oculis had its “buy” rating reaffirmed by HC Wainwright.
• 6/3/2026 – Oculis had its price target lowered by JPMorgan Chase & Co. from $42.00 to $23.00. They now have an “overweight” rating on the stock.
• 6/1/2026 – Oculis had its price target lowered by Robert W. Baird from $49.00 to $38.00. They now have an “outperform” rating on the stock.
• 6/1/2026 – Oculis had its price target lowered by Stifel Nicolaus from $50.00 to $40.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Oculis had its price target lowered by Guggenheim from $75.00 to $45.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Oculis had its price target lowered by HC Wainwright from $47.00 to $26.00. They now have a “buy” rating on the stock.
• 6/1/2026 – Oculis had its price target lowered by Needham & Company LLC from $46.00 to $38.00. They now have a “buy” rating on the stock.
• 5/20/2026 – Oculis is now covered by Guggenheim. They set a “buy” rating and a $75.00 price target on the stock.
• 5/20/2026 – Oculis was upgraded by Guggenheim to “strong-buy”.
• 5/18/2026 – Oculis had its price target raised by JPMorgan Chase & Co. from $38.00 to $42.00. They now have an “overweight” rating on the stock.
• 5/12/2026 – Oculis had its price target raised by Needham & Company LLC from $40.00 to $46.00. They now have a “buy” rating on the stock.
• 5/12/2026 – Oculis had its price target raised by HC Wainwright from $44.00 to $47.00. They now have a “buy” rating on the stock.
• 4/21/2026 – Oculis had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 4/20/2026 – Oculis had its “buy” rating reaffirmed by HC Wainwright. They now have a $44.00 price target on the stock.

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.